Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks
West Cancer Center
« back to all trials
View Trial On ClinicalTrials.gov
ADVANCED SOLID TUMORS: PHASE 1: NKG2A inhibitor: CA047004

A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination with Nivolumab or
Cetuximab in Participants with Advanced Solid Tumors

Title
Bristol-Myers Squibb CA047004 (Phase 1 NKG2A inhibitor)
Study Title

A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination with Nivolumab or
Cetuximab in Participants with Advanced Solid Tumors

Site Link
NCT04349267
Malignancy
Advanced Solid Tumors, renal cell, head and neck cancer (SCCHN), non-small cell lung cancer (NSCLC)
Stage
Stage 4
Disease Setting
ADVANCED/METASTATIC
Line Of Therapy
> or = 2nd line
Investigational Agent
BMS-986315 with either nivolumab or cetuximab
Drug Class
NKG2A inhibitor
PI
Dan Vaena, MD
Sponsor
Bristol-Myers Squibb
Phase
Phase 1
Status
Open to Enrollment
Key Eligibility Criteria
Key Eligibility Criteria Details
  • Renal cell, NSCLC, or SCCHN
  • Must have received prior PD-1 or PD-L1 inhibitor
  • ECOG PS 0-1
  • No known autoimmune disease
  • No need for steroids or other immunsuppressive medicine
  • No interstitual lung disease or pulmonary fibrosis
Objective
  • Primary- 
    • AEs
    • SAEs
    • Number of deaths
  • Secondary
    • ORR
    • DoR
    • PFS
    • PK
Assessment Frequency
_
Assessment Frequency 2
_



Assessment Frequency Link
Path
Dosing Frequency
Control Agents
Study Protocol
Randomized
No
« back to all trials
View Trial On ClinicalTrials.gov
X